Objectives :- The study was performed with the aim to compare HER-2/neu over expression with age, size of tumor, histopathological type, grade of tumor, lymph node positivity, NPI, and hormone receptors ER and PR. Methods :- The study was conducted on 66 cases of breast carcinoma. All the cases underwent immunohistochemistry for ER, PR and HER-2/neu over expression. HER-2/neu over expression was compared with prognostic factors. Results :- The age range of these patients was from 30-70 years with mean age of 49.92 years. HER-2/neu was strongly positive (score 3) in 12/66 ( 18.18%), moderate or equivocal ( score 2) in 7 /66 (10.60 %) and mild ( score 1) in 16/66 (24.24%) and it was negative ( score 0) in 31/66 (46.97 %). Estrogen Receptor ( ...
OBJECTIVE: To determine whether receptor status and HER-2/neu status remains same in primary and met...
OBJECTIVE: To determine whether receptor status and HER-2/neu status remains same in primary and met...
Aim: HER-2/neu amplification occurs in 15-25% of breast carcinomas. This oncogene, also referred to ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Breast cancer is common worldwide and has high morbidity and mortality. Most of the patients in Indi...
Introduction: Breast cancer is leading cancer in women, and the incidence of breast cancer in India ...
Objective: Study was designed to evaluate the expression status of HER2/neu receptor in breast cance...
Background: Breast cancer is the most common cancer in woman that originates from the uncontrolled g...
Objective: The main purpose of this study was to evaluate the condition of the HER-2/Neu receptor in...
OBJECTIVE: To determine whether receptor status and HER-2/neu status remains same in primary and met...
OBJECTIVE: To determine whether receptor status and HER-2/neu status remains same in primary and met...
Aim: HER-2/neu amplification occurs in 15-25% of breast carcinomas. This oncogene, also referred to ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Introduction:Carcinoma of the breast is the most common malignancy of women in Karachi. The current ...
Breast cancer is common worldwide and has high morbidity and mortality. Most of the patients in Indi...
Introduction: Breast cancer is leading cancer in women, and the incidence of breast cancer in India ...
Objective: Study was designed to evaluate the expression status of HER2/neu receptor in breast cance...
Background: Breast cancer is the most common cancer in woman that originates from the uncontrolled g...
Objective: The main purpose of this study was to evaluate the condition of the HER-2/Neu receptor in...
OBJECTIVE: To determine whether receptor status and HER-2/neu status remains same in primary and met...
OBJECTIVE: To determine whether receptor status and HER-2/neu status remains same in primary and met...
Aim: HER-2/neu amplification occurs in 15-25% of breast carcinomas. This oncogene, also referred to ...